Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Toll-Like Receptors (TLRs) agonists are relevant to bladder cancer mainly because intravesical BCG is the classic and clinically established example; it exerts antitumor activity at least in part through TLR2 and TLR4 signaling, especially in non-muscle-invasive bladder cancer (NMIBC). Beyond BCG, other TLR agonists such as TLR7, TLR9, and TLR3 activators have shown preclinical or early clinical interest, but they are not established standard bladder cancer therapies
see also:
[Bladder cancer & Drugs/Treatments](brain://ZHNB4Bvie0yRhbt_wugwig/BladderCancerDrugsTre…